Department of Biomolecular Sciences Weizmann Institute of Science Rehovot Israel

Department of Biomolecular Sciences Weizmann Institute of Science Rehovot Israel; 1st Medical Faculty at Biocev Charles University Prague Czechia

Division of Systems Virology Department of Microbiology and Immunology The Institute of Medical Science The University of Tokyo Tokyo Japan

Division of Systems Virology Department of Microbiology and Immunology The Institute of Medical Science The University of Tokyo Tokyo Japan; Graduate School of Medicine The University of Tokyo Tokyo Japan

Division of Systems Virology Department of Microbiology and Immunology The Institute of Medical Science The University of Tokyo Tokyo Japan; International Vaccine Design Center The Institute of Medical Science The University of Tokyo Tokyo Japan; International Research Center for Infectious Diseases The Institute of Medical Science The University of Tokyo Tokyo Japan; Graduate School of Medicine The University of Tokyo Tokyo Japan; Graduate School of Frontier Sciences The University of Tokyo Kashiwa Japan; Collaboration Unit for Infection Joint Research Center for Human Retrovirus infection Kumamoto University Kumamoto Japan; CREST Japan Science and Technology Agency Kawaguchi Japan

Zobrazit více v PubMed

Ito J, Suzuki R, Uriu K, et al. Convergent evolution of the SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1·1 variant. bioRxiv. 2022 doi: 10.1101/2022.12.05.519085. published online Dec 5. (preprint). PubMed DOI PMC

Tamura T, Ito J, Uriu K, et al. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants. bioRxiv. 2022 doi: 10.1101/2022.12.27.521986. published online Dec 27. (preprint). PubMed DOI PMC

Yamasoba D, Kimura I, Nasser H, et al. Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike. Cell. 2022;185:2103–2115. PubMed PMC

Yamasoba D, Kosugi Y, Kimura I, et al. Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies. Lancet Infect Dis. 2022;22:942–943. PubMed PMC

Kimura I, Yamasoba D, Tamura T, et al. Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5. Cell. 2022;185:3992–4007. PubMed PMC

Saito A, Tamura T, Zahradnik J, et al. Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant. Cell Host Microbe. 2022;30:1540–1555. PubMed PMC

WHO XBB.1.5 rapid risk assessment. 2022. https://www.who.int/docs/default-source/coronaviruse/11jan2023_xbb15_rapid_risk_assessment.pdf?sfvrsn=73e431e8_3

Yue C, Song W, Wang L, et al. Enhanced transmissibility of XBB.1.5 is contributed by both strong ACE2 binding and antibody evasion. bioRxiv. 2023 doi: 10.1101/2023.01.03.522427. published online Jan 5. (preprint). PubMed DOI PMC

Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants

Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant